Complete and long‑term response of HER2 positive locally highly advanced metastatic breast cancer – case report

04/2019

MUDr. Lenka Rušinová; doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Marián Liberko

Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha

SUMMARY

Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.

Key words

breast cancer, locally advanced cancer, HER2 positive cancer, targeted treatment